Can-Fite BioPharma Ltd. (CANF) stock

CANFNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026Score 1/30

$1.49−0.06 (-3.87%)

Close on Nov 12, 2026Market cap $1.95MP/E –Yield –

Can-Fite BioPharma statistics

79 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Jun 30, 2026
Share price as of: Nov 12, 2026

Valuation ratiosIndustry

Market Cap: $1.95M; $280.48M
Enterprise Value: -$1.04M; $148.62M
PS Ratio: 4.82; 3.60
PB Ratio: 0.40; 2.05
P/TBV Ratio: 0.40; 2.29

Enterprise valuationIndustry

EV / Sales: -2.57; 2.60

Share statisticsIndustry

Shares Outstanding: 3M; 58M
Shares Change (YoY): 127.0%; 10.9%
Float: 3M; 49M
Shares Held by Insiders: 0.00%; 12.1%
Shares Held by Institutions: 1.92%; 56.4%

Short sellingIndustry

Short Interest: 31,345; –
Short Interest Change: -7.20%; -0.76%
Days to Cover: 1.00; 5.13

Stock price statisticsIndustry

52-Week High: $12.30; –
52-Week Low: $1.46; –
20-Day Moving Average: $1.69; –
50-Day Moving Average: $1.97; –
200-Day Moving Average: $3.09; –
Average True Range (14): $0.10; –
Price Change (1 Week): -6.88%; 1.51%
Price Change (1 Month): -22.8%; -2.35%
Price Change (3 Months): -56.2%; -21.1%
Price Change (6 Months): -57.3%; -22.6%
Price Change (YTD): -62.7%; -22.6%
Price Change (1 Year): -81.2%; -20.7%
Price Change (3 Years): -96.1%; -27.4%
Price Change (5 Years): -99.4%; -77.3%
Price Change (10 Years): -100.0%; -62.7%
Average Volume (10 Days): 34,634; –
Average Volume (20 Days): 71,992; –
Average Volume (90 Days): 294,019; –
Relative Volume: 0.33; 0.79
Relative Strength Index (14): 26.7; 44.7
Volatility (1 Year): 104.1%; 80.4%
Beta (5 Years): 1.10; 1.07

MarginsIndustry

Operating Margin: -2456.8%; -38.7%
Pretax Margin: -2426.7%; -11.8%
Profit Margin: -2426.7%; -32.0%
EBITDA Margin: -2450.9%; -27.7%
FCF Margin: -2210.1%; -9.20%

Returns on capitalIndustry

Return on Equity (ROE): -217.5%; -51.2%
Return on Assets (ROA): -124.6%; -40.6%
Return on Capital Employed (ROCE): -170.7%; -38.0%

Financial positionIndustry

Current Ratio: 3.60; 3.30
Quick Ratio: 1.34; 2.42
Interest Coverage: -35.04; -6.35

GrowthIndustry

Revenue Growth (YoY): -39.9%; 7.01%
Revenue Growth (3Y CAGR): -20.6%; 2.25%
Revenue Growth (5Y CAGR): -11.9%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.05; 0.40
Revenue Per Employee: $81.00K; $429.29K
Profits Per Employee: -$1.97M; -$683.67K
Employee Count: 5; 75
WACC: 10.5%; 10.1%

Income statement (TTM)Industry

Revenue: $405.00K; $66.37M
Operating Income: -$9.95M; -$20.99M
Pretax Income: -$9.83M; -$13.23M
Net Income: -$9.83M; -$21.61M
EBITDA: -$9.93M; -$16.85M
EPS (Diluted): -$5.97; -$0.75

Balance sheetIndustry

Cash & Short-Term Investments: $2.99M; $67.63M
Net Cash (Debt): $2.99M; $17.46M
Net Cash Per Share: $1.14; $0.72
Equity (Book Value): $4.86M; $53.27M
Book Value Per Share: $1.85; $1.50
Tangible Book Value: $4.86M; $26.82M
Working Capital: $5.78M; $79.47M

Cash flow (TTM)Industry

Operating Cash Flow: -$8.95M; -$12.27M
Capital Expenditures: -$2.00K; -$944.00K
Free Cash Flow: -$8.95M; -$18.20M
FCF Per Share: -$3.42; -$0.42

Dividends and yieldsIndustry

Earnings Yield: -503.8%; -20.8%
FCF Yield: -458.9%; -9.58%
Buyback Yield: -150.4%; -0.73%
Shareholder Yield: -150.4%; 0.00%

Taxes and interestIndustry

Interest Expense: $284.00K; $2.93M

Scores and fair valueIndustry

Altman Z-Score: -34.22; 0.30
Piotroski F-Score: 2; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	CANF	S&P 500	Difference	CANF per year	S&P 500 per year
1 month	-23.6%	-2.7%	−20.9 pts
3 months	-56.7%	-1.7%	−54.9 pts
Year to date	-62.7%	+11.9%	−74.6 pts
1 year	-80.8%	+12.0%	−92.7 pts
3 years	-96.2%	+78.2%	−174.3 pts	-66.3%	+21.2%
5 years	-99.4%	+73.2%	−172.7 pts	-64.6%	+11.6%
10 years	-100.0%	+309.6%	−409.6 pts	-57.1%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M CANF shares were sold short on Oct 30, 2026, down 7.2% from the previous report. At recent volumes it would take 1.0 days to buy them back. Over the last 20 sessions, 32.2% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	31,345	-7.2%	101,449	1.0
Oct 15, 2026	33,776	-39.3%	32,046	1.1
Sep 30, 2026	55,612	-6.3%	47,321	1.2
Sep 15, 2026	59,379	-4.0%	2,140,558	1.0
Aug 31, 2026	61,837	+0.0%	31,522	2.0
Aug 14, 2026	61,815	-6.5%	37,194	1.7
Jul 31, 2026	66,087	-40.0%	41,646	1.6
Jul 15, 2026	110,193	-65.7%	6,157,256	1.0
Jun 30, 2026	321,495	+583.3%	2,602,702	1.0
Jun 15, 2026	47,052	-30.6%	31,756	1.5
May 29, 2026	67,832	-41.8%	22,190	3.1
May 15, 2026	116,564	+397.8%	192,517	1.0

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Can-Fite BioPharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3000 reverse split on Mar 26, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CANF.

Compare: CANF vs XTLB · CANF vs LIPO · CANF vs SCNX · CANF vs RLYB · CANF vs RDHL

Revenue growth-39.9% · median -27.5%

Operating margin-2456.8% · median -3484.4%

Net margin-2426.7% · median 2405.0%

Company	Revenue	Growth
RLYB	$434.00K	-35.6%
CANF	$405.00K	-39.9%
LIPO	$389.78K	-19.4%
XTLB	–	–
SCNX	–	–
RDHL	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 5
Held by institutions: 1.9%
Auditor: KOST FORER GABBAY& KASIERER
SEC CIK: 1536196

Advertisement
300 × 250

See a number that looks wrong?